Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

未开盘 05-27 16:00:00 EDT

31.66

+0.86

+2.79%

最高32.25	最低30.75	成交量175.45万
今开31.30	昨收30.80	日振幅4.87%
总市值36.58亿	流通市值34.83亿	总股本1.16亿
成交额5,562万	换手率1.59%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":31.66,"timestamp":1779912000000,"preClose":30.8,"halted":0,"volume":1754484,"delay":0,"changeRate":0.027922077922077904,"floatShares":110000000,"shares":115554295,"eps":-4.16,"marketStatus":"未开盘","change":0.86,"latestTime":"05-27 16:00:00 EDT","open":31.3,"high":32.25,"low":30.75,"amount":55623813.348168,"amplitude":0.048701,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.16,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779955200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":30.8,"postHourTrading":{"tag":"盘后","latestPrice":31.75,"preClose":31.66,"latestTime":"19:59 EDT","volume":32995,"amount":1047483.4347,"timestamp":1779926371845,"change":0.09,"changeRate":0.002843,"amplitude":0.011368},"volumeRatio":0.965352,"impliedVol":0.7124,"impliedVolPercentile":0.136},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"1125765038","title":"Viking Therapeutics在2026年欧洲肥胖症大会上公布VK2735口服给药二期VENTURE试验13周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125765038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125765038?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:06","pubTimestamp":1778583978,"startTime":"0","endTime":"0","summary":"Viking Therapeutics公司在2026年欧洲肥胖症大会上，公布了其候选药物VK2735口服给药二期VENTURE试验为期13周的研究数据。\n该试验旨在评估VK2735在肥胖或超重成人中的疗效与安全性。公布的数据涵盖了药物对患者体重、腰围及其他相关代谢指标的影响。\n研究结果显示，经过13周的治疗，接受VK2735治疗的患者在体重减轻方面取得了具有统计学意义的改善。此外，药物在试验中展现出了可接受的安全性特征。\n这些积极数据进一步支持了VK2735作为一种潜在的口服肥胖治疗方案的持续开发。公司计划基于这些结果，推进该药物的后续临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4139","BK4585","VKTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRK","BK4585","LU2328871848.SGD","01801","SG9999002232.USD","HK0000165453.HKD","LU1066053197.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU0225771236.USD","LU0455707207.USD","BK4581","RHHBY","LU0234572021.USD","LU0058720904.USD","BK1161","SG9999013999.USD","LU2097828714.EUR","IE00B19Z3581.USD","AZN","BK4534","LU1894683348.USD","IE00BBT3K403.USD","LU2242644610.SGD","NVO","BK1589","LU0321505439.SGD","BK4550","LU0321505868.SGD","LU0985481810.HKD","LU1066051498.USD","LU2097828631.EUR","LU2097828805.USD","SG9999001176.USD","LU1894683264.USD","LU2488822045.USD","LU0868494617.USD","PFE","000963","BK4592","LU0306807586.USD","LU1057294990.SGD","SG9999001176.SGD","LU0170899867.USD","LU1023059063.AUD","LU0122379950.USD","LLY","LU2097828474.EUR","LU0456855351.SGD","IE00BLSP4452.SGD","LU0502904849.HKD","BK4533","VKTX","SG9999002224.SGD","BK4007","IE00B19Z3B42.SGD","LU1883839398.USD","BK4568","SG9999011175.SGD","BK4588","BK1583","LU0225284248.USD","IE0002270589.USD","LU1969619763.USD","LU2097828557.USD","SGXZ57979304.SGD","SG9999003800.SGD","BK4599","LU0306806265.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2610109927","title":"美股异动丨Viking Therapeutics大涨超15%，计划推进口服减肥药后期测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2610109927","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610109927?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:46","pubTimestamp":1770907601,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e5db213c79b1d6cae9b15cb2be74db22","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4539","RWM","TWM","TNA","BK4581","UWM","MNQmain","TZA","BK4585","VKTX","BK4007","BK4534","BK4588","SRTY","BK4139","IWN","BK4535","IWO","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611115500","title":"Viking Therapeutics, Inc.股价飙升18.04% 市值涨6.87亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611115500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611115500?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:31","pubTimestamp":1770906662,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时31分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨18.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Viking Therapeutics, Inc.、Lunai Bioworks Inc.、Tyra Biosciences, Inc.涨幅较大，Onconetix, Inc.、Quince Therapeutics, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为257.06%、76.25%、29.86%，振幅较大的相关个股有Cytomed Therapeutics Limited、Cue Biopharma, Inc.、Karyopharm Therapeutics Inc.，振幅分别为10.44%、9.33%、9.09%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223103a49ce736&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223103a49ce736&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","BK4585","LENZ","BK4539","BK4588","VKTX","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610924388","title":"美股异动丨Viking Therapeutics盘前大涨超16%，公布口服减肥药后期测试计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2610924388","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610924388?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:47","pubTimestamp":1770904031,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e5db213c79b1d6cae9b15cb2be74db22","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","TNA","IWO","BK4550","BK4585","VKTX","TWM","SRTY","BK4588","BK4535","TZA","RWM","BK4539","BK4139","MNQmain","BK4007","UWM","BK4581","IWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160970913","title":"盘前｜Fastly暴涨超40%，存储概念延续强势，思科、APP、QS下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1160970913","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160970913?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:26","pubTimestamp":1770899186,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段小幅走高。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d74fcb174b8df61ab71c001378d38305","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","SNDK","FSLY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1170964209","title":"Viking Therapeutics盘前股价飙升11.7%，公司计划推进口服减肥药进入后期试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1170964209","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170964209?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:14","pubTimestamp":1770891260,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc. (VKTX) 股价在盘前交易时段大幅上涨11.7%，此前该公司宣布计划将其口服肥胖症治疗药物推进至后期试验阶段。这一积极的市场反应凸显了投资者对该公司在代谢疾病治疗领域研发进展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e5db213c79b1d6cae9b15cb2be74db22","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4599","BK4139","BK4585","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132543371","title":"盘前异动｜Fastly暴涨近40%，存储概念延续强势，思科绩后跌近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132543371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132543371?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:15","pubTimestamp":1770887757,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段小幅走高。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5a7e4615a12ff127b4b8e4b4013943bc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDK","VKTX","FSLY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1171356215","title":"异动解读 | Viking Therapeutics盘前大涨12.26%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1171356215","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171356215?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:15","pubTimestamp":1770887731,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.今日盘前股价大涨12.26%，引起了市场的高度关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的一个重要因素，因为目前还没有其他双效或三效激动剂同时提供这两种剂型。中期研究数据显示，VK2735口服片剂每日一次，在13周后帮助患者平均体重下降达12.2%。此外，公司表示其充足的现金储备将支持VK2735的后期研究顺利完成。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e5db213c79b1d6cae9b15cb2be74db22","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118244840","title":"异动解读 | Viking Therapeutics夜盘大涨9.91%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118244840","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118244840?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:06","pubTimestamp":1770858369,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（VKTX）在今日夜盘交易中股价大涨9.91%，引起了市场的广泛关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的重要优势，因为目前尚无其他同类药物同时提供这两种剂型。中期研究数据显示，VK2735口服片剂每日一次，在13周后帮助患者平均体重下降达12.2%。这一进展被视为公司在肥胖症治疗领域的重要里程碑，增强了投资者对其药物商业化前景和未来增长潜力的信心，从而推动了股价在夜盘时段的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142794644","title":"异动解读 | Viking Therapeutics盘后大涨10.40%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1142794644","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142794644?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:08","pubTimestamp":1770847717,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（VKTX）今日盘后股价大涨10.40%，引起了市场的高度关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的一个重要因素，因为目前还没有其他双效或三效激动剂同时提供这两种剂型。后期研究结果表明，VK2735口服片剂每日一次，13周后体重平均下降达12.2%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605323537","title":"Viking Therapeutics, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605323537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605323537?lang=zh_cn&edition=full","pubTime":"2026-01-24 04:30","pubTimestamp":1769200210,"startTime":"0","endTime":"0","summary":"北京时间2026年01月24日04时30分，Viking Therapeutics, Inc.股票出现波动，股价快速下跌5.00%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124043011a44f7ec4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124043011a44f7ec4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4539","BK4599","VKTX","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603646052","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大涨5.05%报32.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603646052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603646052?lang=zh_cn&edition=full","pubTime":"2026-01-15 00:02","pubTimestamp":1768406550,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日00时02分，Viking Therapeutics, Inc.股票出现异动，股价急速拉升5.05%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115000231a4c3ef1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115000231a4c3ef1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4539","BK4007","BK4139","LENZ","VKTX","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149539645","title":"Viking Therapeutics公布双靶点激动剂VK2735二期临床试验结果 获《肥胖》期刊刊载","url":"https://stock-news.laohu8.com/highlight/detail?id=1149539645","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149539645?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219466,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（纳斯达克代码：VKTX）近日宣布，其研发的双重GLP-1/GIP受体激动剂VK2735的二期VENTURE临床试验结果，已正式发表于国际权威期刊《肥胖》（Obesity）。该研究针对肥胖症患者展开，数据显示VK2735在体重管理方面展现出显著疗效与良好安全性。\n此次发表标志着VK2735的临床数据获得学术界的专业认可，为后续研发及商业化进程提供了重要科学依据。公司表示将继续推进该药物的临床开发，探索其在代谢疾病治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4599","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126995143","title":"Viking Therapeutics宣布完成VK2735肥胖维持剂量临床试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1126995143","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126995143?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:13","pubTimestamp":1767874431,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc. (VKTX) 已正式完成其候选药物VK2735针对肥胖症的维持剂量临床试验患者招募工作。该里程碑标志着该药物研发项目进入关键新阶段，为后续疗效数据分析奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4599","BK4139","BK4585","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149069374","title":"诺和诺德减肥药Wegovy新版药片已上市，竞争对手Lilly和Viking股票反应如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=1149069374","media":"老虎资讯综合","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149069374?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:22","pubTimestamp":1767691330,"startTime":"0","endTime":"0","summary":"诺和诺德旗下大获成功的肥胖治疗药物现已推出口服剂型，成为美国首个用于减重的GLP-1口服药物。该口服药提供四种剂量规格，价格低于注射版Wegovy。针对拥有商业健康保险的患者，诺和诺德提供优惠券可将月费用减免至25美元。诺和诺德股价周一上涨5.2%，这可能得益于这家丹麦制药商在与肥胖药物市场另一主导者礼来的长期竞争中获得的首发优势。在诺和诺德的三期临床试验中，服用最高剂量Wegovy口服药的患者平均减重达17%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/dc46a35a40167e1ea8ec45d62fa07e24","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/dc46a35a40167e1ea8ec45d62fa07e24"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","LLY","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163752901","title":"“圣诞节可以收礼12天”？2026年这12只股票可作节日佳礼","url":"https://stock-news.laohu8.com/highlight/detail?id=1163752901","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163752901?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:29","pubTimestamp":1766647746,"startTime":"0","endTime":"0","summary":"特斯拉被认为是“美股七巨头”中最“顽皮”的一只股票，仅有45%的分析师给予其“买入”评级，且平均目标价低于当前股价。相比之下，罗素1000指数成分股的平均“买入”评级比例目前约为58%。大型成长股大幅上涨，就像拆开一份期盼已久的圣诞礼物。在罗素1000指数中，只有大约5%的股票，其目标价明显低于当前交易价格。即便是逆向投资者，可能也未必认为这是一份最好的“礼物”。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"13d44e8d649e7e968597cd411f47871e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","FRMI","LOAR","ALK","QXO","AUR","NVDA","MSFT","AMZN","Q","TSLA","RARE","MSTR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2517619311","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅上涨5.01%报29.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517619311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517619311?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:09","pubTimestamp":1741273775,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时09分，Viking Therapeutics, Inc.股票出现波动，股价大幅上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1475.89%、720.61%、73.18%，振幅较大的相关个股有Moolec Science Sa C/Wts 、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为44.44%、42.11%、39.20%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","VKTX","BK4599","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516263769","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516263769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516263769?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013569,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Viking Therapeutics, Inc.股票出现异动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、木薯科学涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为687.62%、115.08%、86.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、40.78%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LENZ","BK4139","BK4588","VKTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514038900","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514038900?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为884.66%、177.60%、104.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VKTX","LENZ","BK4588","BK4599","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0754},{"period":"1month","weight":-0.0402},{"period":"3month","weight":-0.0397},{"period":"6month","weight":-0.1399},{"period":"1year","weight":0.1648},{"period":"ytd","weight":-0.1001}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006749},{"month":2,"riseRate":0.545455,"avgChangeRate":0.220725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.034739},{"month":4,"riseRate":0.454545,"avgChangeRate":0.013541},{"month":5,"riseRate":0.333333,"avgChangeRate":0.073947},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.022105},{"month":7,"riseRate":0.545455,"avgChangeRate":0.01621},{"month":8,"riseRate":0.454545,"avgChangeRate":0.012248},{"month":9,"riseRate":0.272727,"avgChangeRate":0.053956},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}